5-MeO-DMT for Anxiety Disorders

8 papers and 2 clinical trials exploring 5-meo-dmt as a treatment for anxiety disorders.

CompoundTryptamine

5-MeO-DMT

A potent tryptamine psychedelic known for profound mystical experiences, currently under clinical investigation for TRD and anxiety.

Full 5-MeO-DMT profile
Indication300 million worldwide

Anxiety Disorders

Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.

Full Anxiety Disorders profile

Academic Research

8 papers
Paywallindividual

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant adverse events, rapid absorption with peak plasma concentrations at 20 minutes, dose-dependent neurophysiological modulation without full psychedelic effects, and maintenance of normal cognitive and behavioral function.

Published
Journal
Neuropsychopharmacology
Authors
Albarracín, S. G., Bistue Millón, M. B., Bruno, D., Bruno, M. A., Díaz-Dellavalle, P., Diez, P., Feresin, G. E., Garcés, M. A., Kassuha, D. E., Noguera, L., Orosco, L., Ortiz, J. E., Vita, L., Zanino, M.
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
Journal
JAMA Psychiatry
Authors
Graziosi, M., Hinkle, J. T., Nayak, S., Yaden, D. B.
Paywallindividual

A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms

This open-label (naturalistic) study (n=42) with 5-MeO-DMT (smoked) found that it significantly reduced ratings of depression, anxiety, and stress. It also increased scores on mindfulness and life satisfaction. These effects correlated with higher ego dissolution and oceanic boundlessness during the acute experience.

Published
Journal
Psychopharmacology
Authors
Jurok, R., Kuchar, M., Kuypers, K. P. C., Lancelotta, R., Maryska, M., Mason, N. L., Páleníček, T., Rak, J., Ramaekers, J. G., Riba, J., Sulakova, A., Uthaug, M. V., van Oorsouw, K.

Clinical Trials

2 trials

Explore further

Search all 5-MeO-DMT papers Search all Anxiety Disorders trials Full 5-MeO-DMT profile Full Anxiety Disorders profile